What’s on the horizon for higher-risk MDS? An update on emerging novel agents?
Vložit
- čas přidán 19. 02. 2023
- Dr David Sallman reviews recent advances in the management of HR-MDS, including the mode of action and latest clinical data for emerging treatments.
Watch now: touchoncologyime.org/hr-mds-e...
--------
This activity is funded by an independent medical education grant from Gilead Sciences, Inc. and is jointly provided by USF Health and touchIME.
DR. Sallman speaks too quickly! It was disturbing to listen to him.